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Inflammation in skeletal muscle is implicated in the pathogenesis of insulin resistance and cachexia but
why uremia up‐regulates pro‐inflammatory cytokines is unknown. Toll‐like receptors (TLRs) regulate
locally the innate immune responses, but it is unknown whether in chronic kidney disease (CKD)
TLR4 muscle signalling is altered. The aim of the study is to investigate whether in CKD muscle,
TLRs had abnormal function and may be involved in transcription of pro‐inflammatory cytokine.
Methods
TLR4, phospho‐p65, phospho‐ikBα, tumour necrosis factor (TNF)‐α, phospho p38, Murf 1, and atrogin
were studied in skeletal muscle from nondiabetic CKD stage 5 patients (n = 29) and controls (n = 14)
by immunohistochemistry, western blot, and RT–PCR. Muscle cell cultures (C2C12) exposed to
uremic serum were employed to study TLR4 expression (western blot and RT–PCR) and TLR‐driven
signalling. TLR4 signalling was abrogated by a small molecule chemical inhibitor or TLR4 siRNA.
Phospho AKT and phospho p38 were evaluated by western blot.
Results
CKD subjects had elevated TLR4 gene and protein expression. Also expression of NFkB, p38 MAPK
and the NFkB‐regulated gene TNF‐α was increased. At multivariate analysis, TLR4 protein content
was predicted by eGFR and Subjective Global Assessment, suggesting that the progressive decline in
renal function and wasting mediate TLR4 activation. In C2C12, uremic serum increased TLR4 as well
as TNF‐α and down‐regulated pAkt. These effects were prevented by blockade of TLR4.
Conclusions
CKD promotes muscle inflammation through an up‐regulation of TLR4, which may activate downward
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inflammatory signals such as TNF‐α and NFkB‐regulated genes.
Keywords: Chronic kidney disease, Toll‐like receptors, Muscle wasting, Inflammation, Tumour
necrosis factor‐α
Introduction
Although uremic cachexia has for a long time been regarded as a non‐immune disease [see Ref. 1 for
Review], an emerging hypothesis is that innate immunity plays a role in its development and
progression,1, 2, 3 in analogy with cancer4 and cardiac5 cachexia. Initial observations have shown that
circulating levels of C‐reactive protein (CRP) and proinflammatory cytokines, including interleukin‐6
(IL‐6) and tumour necrosis factor‐α (TNF‐α), are increased in blood of patients with CKD and are
strongly associated with wasting.6, 7 More recently, an up‐regulation of several genes associated with
inflammation in muscle has been demonstrated to occur both in rodents models8, 9 and humans with
CKD.10, 11, 12 Pro‐inflammatory cytokines, mainly TNF‐α and IL‐6, have per se catabolic effects on
skeletal muscle by accelerating protein degradation or reducing protein synthesis.13, 14, 15 In addition,
in CKD proinflammatory cytokines cause a resistance to the action of insulin16 and GH/IGF‐1.17, 18
Bailey et al. recently identified a series of abnormal postreceptor signalling changes in the insulin/IGF‐
1 pathway leading to atrophy in muscle of rats with CKD.19 These include the occurrence of
functional abnormalities in the IRS/PI3‐K cascade that decrease the phosphorylation of the downstream
effector Akt and the stimulation of the expression of specific E3 ubiquitin conjugating enzymes,
atrogin‐1/MAFbx and MuRF1 with acceleration of protein degradation.19, 20 Of note, we could
observe that the pAkt signal is markedly down‐regulated in muscle of patients with advanced CKD and
is associated with apoptotic cell loss, suggesting that insulin resistance is a major player in the
regulation of muscle cell survival and catabolism in renal patients.12 In addition, Zhang et al. could
recently demonstrate that high IL‐6, by the activation of the JAK‐Stat3 pathway, up‐regulates the gene
expression of myostatin, a major negative regulator of muscle protein content and regeneration. Such a
mechanism has been observed both in the rodent model and in muscle of CKD patients.9 Interestingly,
Myiamoto et al.21 observed that increased circulating follistatin, which neutralizes the biologic
activities of myostatin, occurred together with inflammation and reduced muscle strength in a large
cohort of stage V CKD patients, suggesting an involvement of the myostatin regulation system in the
uremic wasting process.
Despite our increased understanding of mechanisms by which systemic inflammation regulates the
pathways leading to muscle catabolism in uremia, the reason(s) why uremia up‐regulates pro‐
inflammatory cytokines in skeletal muscle is unknown. Skeletal muscle possesses both the afferent and
efferent limbs of the innate immune system, including Toll‐like receptors (TLRs) and both early‐ and
late‐phase cytokines.22, 23, 24 TLRs are a family of receptors in the innate immune system which
mediate signal transduction pathways through the activation of transcription factors that regulate the
expression of proinflammatory cytokines in several cell types and tissues.22 In skeletal muscle, TLRs
act as a sentinel to monitor for the presence of pathogens23 and, upon activation, induce a local
inflammatory response24, 25 culminating in the translocation of NFkB to the nucleus and activation of
inflammatory genes, including TNF‐α, IL‐1ß, and IL‐6. In addition to microbial products, TLRs can
also be activated by endogenous signals of tissue injury, including debris from apoptotic and necrotic
cells, oligosaccharides, heat shock proteins, and nucleic acid fragments.26, 27
In this study we hypothesize that CKD patients have abnormal function of TLRs in muscle and that
TLRs may be involved in initiating events associated with the stimulation of muscle pro‐inflammatory
cytokine transcription. We tested this postulate by different measures. First we studied TLR gene and
protein expression in muscle biopsies of patients with CKD and compared the results to those obtained
in subjects with normal renal function. As a second step, to identify specific TLR‐linked transcriptional
pathways we studied the expression profiles of selected TLR4 downward genes and molecules in
uremic muscle. As a third step, we studied the clinical correlations associated with muscle TLR4
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expression and we observed that TLR4 protein expression is inversely related to residual renal
function, suggesting that more advanced uremic state activates muscle TLR4. Additionally, we studied
the response to uremic serum of C2C12 myotubes and we observed that uremic serum up‐regulates
TLR4 and TNF‐α expression and down‐regulates pAkt. Such effects are prevented by TLR4 inhibitors
or TLR4 knockdown. Overall, our data demonstrate the activation of TLR4 and its downward
inflammatory cascade in muscle of subjects with CKD and suggest that enhanced TLR4 signalling
contributes to the up‐regulation of native immunity in skeletal muscle in uremia.
Methods
Study participants
Starting from 5 September 2005, 29 nondiabetic CKD patients (18 M/11 F) scheduled for peritoneal
dialysis catheter insertion were eligible for enrolment in this protocol at the Nephrology Division,
Department of Internal Medicine, University of Genoa (Table 1). The study was part of a protocol on
the effects of peritoneal dialysis on protein turnover approved by the Ethical Committee of the
Department of Internal Medicine of the University of Genoa. All subjects were informed about the
nature, purposes, procedures, and possible risks of the study, before their informed consents were
obtained. The procedures were in accordance with the Helsinki declaration regarding ethics of human
research. Patients younger than 18 and older than 85 years were excluded from the study. The patients
were enrolled in the study on a consecutive basis if they did not meet the following exclusion criteria:
New York Heart Association Class III–IV congestive heart failure, a recent (<12 months) myocardial
infarction, liver cirrhosis, infection, or diabetic nephropathy. Clinical and biochemical characteristics of
the subjects are shown in Table 1. All groups were closely matched for age and gender. All subjects
had a sedentary life style. Their mean age was 67 years (range 43–82 years). Their estimated28 GFR
was 8 ± 1 mL/min 1.73 m  (range 4–14 mL/min).
Table 1
Clinical characteristics of controls and chronic kidney disease
(CKD) subjects
Causes of renal diseases were hypertensive nephrosclerosis (11 patients), chronic glomerulonephritis (8
patients), tubulointerstitial nephritis (3 patients), polycystic kidney disease (6 patients), and obstructive
uropathy (1 patient). Their mean estimated protein and calorie intake were 0.9 g/kg and 27 kcal/kg,
respectively. Their nutritional status was measured with the 7‐point Subjective Global Assessment
(SGA) index.29, 30 By this approach, an overall SGA classification of 1–7 is assigned; a score of 7
indicates a normal nutritional status and a score of 1 indicates severe protein‐energy wasting. Albumin
levels were low (<3.8 g/100 mL) in 14 subjects, while BMI was low (<23 kg/m ) in six subjects. The
evidence of an inflammatory response (CRP >5 mg/L) was shown in 11 subjects.
Mean muscle fibre cross‐sectional area (CSA) was lower in patients with CKD (median = 976 µm ,
range 745–1615; controls median = 1422 µm , range 1100–1974) (P < 0.05), suggesting muscle
atrophy. CKD subjects were more insulin resistant than control subjects, based on a higher HOMA
index and plasma insulin concentration (P < 0.05).
Control biopsies were taken in 14 otherwise healthy subjects, during elective surgery for abdominal
wall hernias. Controls were selected on the basis of having no chronic illnesses or acute inflammatory
processes. In these subjects baseline physical examination and eGFR (99 ± 6, range 78–120 mL/min) as
well as screening biochemical tests of renal, hepatic, haematological, and metabolic function (thyroid






Muscle biopsies were obtained from rectus abdominis muscle, at the beginning of surgery. Tissue (90 
mg) RNA was isolated using the Qiazol Lysis reagent (Qiagen Sciences, Maryland, USA). Isolated
RNA was stored at −80 °C until use. Other sample aliquots were used for immunohistochemical
staining, and for protein (western blot) analysis. For the study of fat infiltration, tissue samples were
stained with Oil‐red‐O, which detect lipids, mainly neutral fats and cholesteryl esters (Sigma‐Aldrich,
Milan, Italy) (31). Digital images of immunohistochemical and Oil‐red‐O stained sections were
obtained using a Leica microscope (Leica Microsystems GmbH Wetzlar, Germany) equipped with a
digital camera controlled by Q500MC Software‐Qwin (Leica).12
Tissue analyses
Histological preparation, immunohistochemical staining, and Western blot were performed as
previously described.12 mRNAs were analysed by RT–PCR as described [53]. Primers are listed in
Table 2. Relative mRNA levels were calculated from cycle threshold (Ct) values using β‐actin as the
internal control.
Table 2
Primer sequences for RT–PCR analyses
Cell culture and treatments
Mouse skeletal muscle cell line C2C12 was propagated as myoblasts in DMEM (Euroclone, Milan,
Italy) containing 2 mmol L‐glutamine and 100 U/mL penicillin‐streptomycin (Euroclone), with 5%
FBS and incubated at 37 °C. For differentiation into myotubes, the myoblasts at 90% confluence were
incubated with DMEM plus 2% horse serum (Sigma Chemical Co, St. Louis, MO, U.S.A.). The
myotubes began to form in 2–4 days, and multinucleated muscle fibre cultures were used at 7 days. For
evaluating TLR 4 induction, myotubes were incubated with 10% pooled human normal serum or
pooled human uremic serum.
Experimental conditions
C2C12 mouse myotubes were incubated in the presence of uremic serum or normal serum for 2, 4, and
6 h to assess TLR4 and PKC expression. TLRs expression was studied by western blot. In selected
experiments, TLR4 and PKC receptor antagonists were added to the cells 1 h before uremic serum
stimulation. C2C12 were blocked for 2 h before uremic serum treatment with 30 µM VIPER (viral
inhibitory peptide of TLR4) or CP7 (inert control peptide, designed as negative control for inhibitory
assay). Cells were exposed to uremic serum for 5 h and then total RNA was extracted using TRIzol,
reverse transcribed, and TNF‐α mRNA expression was analysed by real time PCR, as above described.
Uremic serum
Uremic serum was collected from patients with ESRD on hemodialysis recruited randomly from a pool
of 150 patients at the Nephrology Division at the Genoa University. Patients were recruited over a 2 
month period. Informed consent was obtained, and 3 mL of blood was collected before the next
subsequent hemodialysis. Healthy age‐matched donors were used as controls. Blood urea nitrogen,
creatinine, and glucose were assayed in all patients, and control sera were excluded if creatinine was
>1.0 mg/dL. Exclusion criteria were presence of inflammatory disease, acute or chronic infection,
autoimmune or liver diseases, diabetes, and malignancy. None of the patients or controls smoked.
Blood was collected in Vacutainer tubes, and serum was separated by centrifuging clotted blood at
1100 g for 10 min at room temperature to obtain serum. In order to minimize minor differences
between patients, all serum samples were pooled for the experiments. Serum samples were frozen at 
−20 °C until analysis. In preliminary experiments, 10% was found to be the highest nontoxic
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concentration of uremic serum.
Systemic inflammatory marker detection in uremic serum
Cytokine levels in uremic serum are shown in Table 3. Serum CRP, osteoprotegerin (OPG), TNF‐a,
CCL2, adiponectin, leptin, resistin, IL‐6, soluble IL‐6 receptor (s‐IL‐6R), and osteopontin (OPN)
complex levels were measured by colorimetric enzyme‐linked immunosorbent assay (ELISA) from
R&D Systems (Minneapolis, Minnesota, USA), following manufacturer's instructions. Mean intra‐ and
inter‐assay coefficients of variation (CV) were below 8% for all markers. Serum lipopolysaccharide
quantification was performed using a Limulus Amebocyte assay (Cambrex, Verviers, Belgium).
Table 3
Cytokine levels in normal and uremic serum
Block of Toll‐like receptor 4 by viral inhibitory peptide of Toll‐like receptor 4
C2C12 were blocked, for 2 h before uremic serum treatment, with 30 µM VIPER (viral inhibitory
peptide of TLR4) or CP7 (inert control peptide, designed as negative control for inhibitory assay)
(Imgenex, San Diego, CA). Cells were exposed to uremic serum for 5 h and then total RNA was
extracted using TRIzol, reverse transcribed, and TNF‐α mRNA expression was analysed by real time
PCR, as above described.
RNA interference
C2C12 were transfected with 60 nM TLR4 specific siRNA or negative control siRNA (Ambion,
Carlsbad, CA) using Lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's
protocol and then incubated at 37 °C in a CO  incubator for 24 h until the cells were ready for assay.
The efficacy of knockdown was determined by real‐time PCR.
Statistical analysis
All data are presented as the mean ± standard error of the mean or median (range). Specific mRNAs
were normalized for the internal control gene (β‐actin) and are expressed as transcript/housekeeping
gene ratios. The control treated group mean was given a value of 100, and individual values are
expressed relative to this value. Statistical analysis was performed by using the SPSS statistical
package (version 16; SPSS, Chicago, IL). For statistical analysis of expression variables that did not
have a Gaussian distribution, values were logarithmically transformed or analysed by nonparametrical
tests. Comparisons between groups were performed by one‐way ANOVA with a post hoc Bonferroni
correction or by a Kruskal–Wallis nonparametric test when appropriate. A multivariate regression
model was created to study the predictors of TLR4 content in muscle. Statistical significance occurred
if a computed two‐tailed P < 0.05.
Results
Elevated Toll‐like receptor 4 gene expression and protein content in muscle of patients
with chronic kidney disease
Figures 1 and 2 show TLR2, TLR3, and TLR4 mRNA and protein levels in muscle of controls and
CKD patients. While TLR2 and TLR3 were normally regulated (Figure 1), TLR4 mRNA was
significantly overexpressed (by approximately two‐fold; P < 0.05) in muscle of CKD subjects
compared with controls (Figure 2A). Consistent with the increases in TLR4 gene expression, CKD
subjects had higher TLR4 muscle protein content than control subjects (P < 0.05–0.001) as shown by
immunohistochemistry and western blot (Figure 2B–D).
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Figure 1
Expression of TLR2 (a) and TLR3 (b) mRNAs and proteins in
skeletal muscle of controls (n = 14) and patients with chronic
kidney disease (CKD) (n = 29). TLR2 and TLR3 mRNA
expression was determined by real‐time PCR ...
Figure 2
Expression of TLR4 mRNA (a) and protein (b–d) in normal
skeletal muscle (n = 14) and in patients chronic kidney disease
(CKD) (n = 29). TLR4 mRNA was evaluated by real‐time PCR,
and its protein by immunohistochemistry ...
Toll‐like receptor 4‐driven signalling in skeletal muscle of patients with chronic kidney
disease
As a next step, we examined whether increased TLR4 expression in CKD subjects was associated with
abnormal TLR4 signalling. As a first step we measured the abundance of NF‐kB p65 (phosphorylated
p65 subunit) (p‐p65) and IkB‐α (p‐IkB‐α) in muscle biopsies. Normal muscle showed p‐p65 positive
nuclear staining in a very small percentage (1.7 ± 0.6%) of muscle fibres (Figure 3A). This percentage
significantly rose to 17.4 ± 2.5% in patients with CKD (Figure 3A). Also p‐IkB‐α and TNF‐α
expressions were increased in samples from CKD patients (Figure 3B and 3C, respectively).
Figure 3
(Panel a). Phospho‐p65 (P‐p65) expression in the skeletal muscle
of CKD patients and controls. Control (n = 11) muscle showed p‐
p65 positive nuclei in a very small percentage. This percentage
increased significantly ...
Next, we evaluated the expression and localization of p38 as second messengers for TNF‐α in uremia.
Phosphorylated p38 (p38p) expression was present in the normal muscle at minimal levels. Conversely,
p38p was up‐regulated in CKD patients (Figure 3D).
To understand if different muscle fat infiltration could explain difference in cytokine expression in
CKD, we studied Oil‐red‐O expression (see methods) in muscle biopsies of 10 CKD and 7 control
subjects. Muscle fat infiltration was low and similar in CKD patients and control subjects (mean score
0.012 ± 0.01 and 0.014 ± 0.02, P = NS, respectively, in CKD patients and controls).
Finally, we studied MuRF‐1, a muscle‐restricted ubiquitin ligase involved in the accelerated protein
degradation during various kinds of muscle atrophy and also depending on the TNF‐α/p38 pathway.29,
30 MuRF‐1 was highly up‐regulated in muscles from CKD subjects. In addition also atrogin‐1, another
muscle‐specific ubiquitin ligase triggering muscle atrophy, was up‐regulated (Figure 3E). Collectively,
these results indicate that CKD subjects have increased TLR4 expression/content and TLR4‐driven
signalling.
Clinical determinants of Toll‐like receptor 4 expression in muscle
As a next step, we studied whether TLR4 expression in muscle can be predicted by clinical findings.
Table 4 shows the associations between individual clinical data and logTLR4 content in skeletal
muscle. LogTLR4 content in muscle was inversely related to eGFR, SGA, and haemoglobin levels,
while it was directly related to cholesterol levels. Only as a trend (P < 0.06), muscle LogTLR4 content
was related to serum CRP. There was no relationship between muscle logTLR4 and age, weight, fat
and fat‐free mass, cross‐sectional muscle area, nPNA, estimated calorie intake, serum albumin, BUN,
glucose, bicarbonate, triglycerides, phosphate, fibrinogen, and iron levels. Using the studied variables
for inclusion into multivariate analysis models revealed SGA and eGFR only to contribute individually
and significantly to the prediction of TLR4 expression in skeletal muscle (R  = 0.53, P < 0.001).
Table 4
Univariate and multivariate analysis of the correlation between
LogTLR4 protein expression and clinical characteristics in patients
with CKD (n = 29)
Uremic serum induces Toll‐like receptor 4 expression, p38, and AKT activation in
C2C12 myotubes
To explore whether circulating factors progressively retained in blood in uremia directly stimulate
TLR4 and its driven signalling in muscle, we treated C2C12 myotubes with 10% uremic serum for 0–6 
h. Uremic serum induced a four‐fold increase in TLR4 mRNA after 2 h, an effect which persisted until
6 h. Also TLR4 protein was up‐regulated at 6 h respect to cells exposed to 10% normal serum (Figure 4
A). In addition, uremic serum induced TNF‐α mRNA expression (Figure 4B). Then, we investigated
the effects of uremic serum on AKT and p38 phosphorylation. When C2C12 were exposed to uremic
serum for 24 h, AKT phosphorylation was reduced by 40% with respect to cells treated with normal
serum (Figure 4C). Moreover, uremic serum up‐regulated p38 MAPK phosphorylation within 10 min
(Figure 4D), an effect that persisted for 240 min.
Figure 4
(Panel a). The effect of normal serum (NS) and uremic serum (US)
on TLR4 mRNA and protein in C2C12 myotubes. Cells were
incubated with 10% serum for 6 h. TLR4 mRNA expression was
determined by real time PCR at different times and protein by
western ...
P38 mitogen‐activated protein kinase/protein kinase C is involved in uremic serum‐
induced Toll‐like receptor 4 expression
To further investigate the role of p38 MAPK phosphorylation on uremic serum‐induced TLR4
expression, we examined the role of p38 and its related signal pathway including protein kinase C
(PKC), by the use of p38 MAPK and PKC inhibitors. Pretreatment of C2C12 myotubes with the p38
inhibitor SB203580 (10 µM) or the PKC inhibitors chelerythrine (5 µM), or staurosporine (0.2–0.4 
µM), 1 h before serum exposure resulted in a marked decrease in the serum induced TLR4 mRNA
overexpression (Figure 5). These findings show the implication of the p38MAPK/PKC pathway in
TLR4 activation by uremia.
Figure 5
Effects of p38 inhibitor (10 µM SB203580), and pKC inhibitors
(0.2–4 µM staurosporine or 10 µM chelerythrine) on uremic serum
(US)‐induced TLR4 mRNA. To further investigate the mechanism
...
Toll‐like receptor 4 mediates the effect of uremic serum on Akt signalling
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To evaluate whether the effects of uremic serum on the activation of TLR4 can be prevented by
inhibiting TLR4 signalling, we pre‐incubated the myotubes with VIPER, a specific TLR4 inhibitor,
which acts by directly targeting the TLR4 adaptors Mal and TRAM, thus inhibiting TLR4‐mediated
responses.31 As shown in Figure 6A, preincubation of myotubes with VIPER prevented the ability of
uremic serum to up‐regulate TNF‐α.
Figure 6
Effect of uremic serum (US) on TNF‐α gene expression and pAkt
in C2C12 myotubes treated with TLR4 inhibitors or silenced for
TLR4. (Panel a) Preincubation of myotubes with VIPER, a
specific TLR4 inhibitor, prevented the ability of US to ...
As a next step, we employed gene silencing as an independent, albeit complementary method to
examine the role of uremic serum on TLR4 regulation in muscle. TLR4 siRNA decreased TLR4
mRNA and protein in C2C12 myotubes (Figure 6B). TLR4 gene silencing reduced uremic serum‐
induced TNF‐α (Figure 6C) and recovered AKT signalling (Figure 6D).
Discussion
In this study we tested the hypothesis that a TLR‐driven inflammatory response occurs in skeletal
muscle of patients with CKD. We identified the overexpression of TLR4 in muscle biopsies of stage 5
CKD patients and observed that this response was associated with NF‐kB activation and the
enrichment of multiple members of the NF‐kB dependent inflammatory pathway. NF‐kB is a well‐
recognized downward TLR4 transcription factor that directs the production of TNF‐α and pro‐
inflammatory cytokines which are major mediators of protein breakdown and atrophy in the skeletal
muscle.32, 33
We have previously observed that pAkt is down‐regulated in skeletal muscle of CKD subjects.12 Also
in accordance with one previous observation,9 the TNF‐alpha gene, that is highly regulated by
NFkB,12, 13 was overexpressed in muscle from CKD subjects.TNF‐α is also by itself an activator of
NF‐kB, thus leading to a positive feedback loop which potentiates muscle abnormalities.32 In addition,
TNF‐α activates mitogen‐activated protein kinases (MAPKs), including p38 and JNK33 to increase
protein breakdown by atrogin1/MAFbx gene expression in skeletal muscle.34 We previously observed
up‐regulated JNK in muscle of CKD patients.12 In addition, we observed that p38 MAPK, a second
messenger for TNF‐α,35, 36, 37 is up‐regulated in uremic muscle. The p38 MAPK activity in skeletal
muscle is regulated by several catabolic conditions, such as ageing,38 type 2 diabetes,39 limb
immobilization,40 and neurogenic atrophy,41 suggesting that the TNF‐α/p38 MAPK driven signalling
takes place as a common mechanism in different catabolic conditions.
According to previous observations1, 12 muscle pAkt is down‐regulated in uremia. In muscle
physiology, the activation of the Akt signalling pathway mediates the balance between the anabolic and
catabolic reactions. Inhibition of this pathway up‐regulates, while its activation down‐regulates, the
expression of the transcription factors MAFbx and MuRF‐1 via inhibition of the Foxo family of
transcription factors.19, 33 During atrophy, MuRF‐1 and MAFbx direct the polyubiquitination of
proteins to target them for proteolysis by the 26S proteasome, mediating muscle breakdown.37 As a
signature response of decreased pAkt, we observed also an overexpression of the regulators of protein
degradation atrogin‐1/MAFbx and MuRF1 in muscle from CKD patients.
Collectively, these results indicate that Stage 5 CKD subjects have increased TLR4 expression/content
and TLR4‐driven signalling in muscle. To better understand the significance of our data, we studied the
associations between TLR4 content in muscle and several clinical findings. We observed that both low
SGA score (which indicates an overall concept of impaired nutrition) and eGFR (an index of residual
renal function) play an independent role to predict TLR4 content in muscle of CKD patients. Thus,
according to our findings, both wasting and progressive loss of residual renal function are predictive of
muscle TLR4. The SGA has been validated as reliable tool to assess protein‐energy wasting. A single
SGA assessment has been shown to be associated with morbidity, hospitalization, and risk of short‐
term mortality in dialysis patients. In our study TLR4 content in muscle rose progressively along with
progressive decline of residual renal function, with a two‐fold increase in TLR4 as eGFR declined from
13 to 4 mL/min. However, although TLR4 was associated with SGA, we could not observe an
association between TLR4 and fat free mass in patients with CKD. This finding suggests that TLR4
up‐regulation is a part of the stress response that takes place in overt uremia. In contrast, metabolic
acidosis causes a more precocious (Stage 4) disturbance of muscle protein metabolism in patients with
CKD.42 According to our findings, in patients with CKD metabolic acidosis and up‐regulation of
native immunity are, respectively, part of the early and late muscle stress response.
It is tempting to speculate that in Stage 5 CKD patients the decline of the residual renal function causes
the retention of still unidentified circulating compound(s) which accumulate in uremia and is sensed by
TLRs in muscle. To examine whether uremic milieu directly activates TLR4 signalling in human
muscle, we exposed differentiated C2C12 mice myotubes to uremic serum. Interestingly, uremic serum
rapidly stimulated the mRNA expression of TLR4 and TNF‐α, and depressed pAkt. Moreover, the gene
expression of TNF‐α and pAkt down‐regulation activated by uremic serum were prevented in skeletal
muscle cells by selective TLR4 inhibition or TLR4 knockdown. We conclude that the regulation of
TNF‐α in myotubes by uremic serum is mediated by TLR4 expression and signalling. Overall, our data
suggest that the up‐regulated TLR4 response in muscle of CKD patients translate the metabolic
alterations of uremia into decreased insulin signal and atrophy.
What sensing and signalling mechanisms are involved in TLR4‐dependent immune activation in
uremic muscle? Besides endotoxin,43 a variety of putative endogenous TLR ligands have been
described in the literature, including heat shock proteins that bind TLR4,44 the small ribonuclear RNA
U1 that binds TLR3,45 and various extracellular matrix and membrane components.46 The circulating
molecules which can be sensed by skeletal muscle in uremia to mount a TLR4 response are unknown.
One possibility is that alterations in calcium and/or phosphate metabolism, which increase the risk for
vascular calcification, may act as a yet another nidus for a local inflammatory response.47 However in
patients studied here, TLR4 expression in muscle was not associated with serum phosphate, calcium, or
PTH levels. Another possibility is that some molecule are sensed by muscle as danger signal. In
patients with diabetes, TLRs sense high glucose, high free fatty acids, AGEs, or other molecules,48, 49
as danger signals and subsequently mediate the inflammatory cascade to promote progression of
diabetic complications.49 However, patients studied here had nondiabetic CKD. A number of uremic
retention solutes, such as guanidine compounds, exert pro‐ as well as anti‐inflammatory effects on
monocyte/macrophage function.50 In addition, in recent years the gut microbiota has been linked to
this pathogenesis of inflammation in uremia.51 Specifically, lipopolysaccharide (LPS or endotoxin), an
outer membrane component of Gram negative bacteria, is considered to be a causative factor for insulin
resistance.51 It has been postulated that uremia alter gut flora growth and intestinal wall permeability,
elevating enterobacterial production and translocation of LPS into the systemic circulation.51 In
patients studied here the level of circulating endotoxins was borderline high, suggesting that circulating
endotoxins might be responsible for the changes in TLR4 muscle expression and inflammatory
changes. Clearly, this should be addressed in future studies.
In summary, the present results provide compelling evidence that in uremia the activation of TLR4
present in skeletal muscle cells triggers an innate immune response that mediates a down‐regulation of







ligand that activates TLR4 in this setting remains uncertain.
Our data also suggest that patients with CKD have increased muscle capacity to mount a rapid and
possibly uncontrolled inflammatory response in the presence of TLR4 ligands, such as during an acute
illness or infection. Targeting TLR4 may prove to be a therapeutic modality, improving insulin
signalling and preventing the profound catabolic consequences of insulin resistance in CKD.
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